Modeling the Uterus to Fight Endometriosis

Endometriosis affects more than 190 million women worldwide, causing chronic pain, infertility, and a cascade of downstream health complications — yet the disease remains chronically under-researched and under-treated. Diagnosis often takes years, and the therapeutic options available today largely manage symptoms rather than address the underlying biology. Metri Bio was founded to close that gap by giving drug developers a fundamentally better tool: living, three-dimensional models of the human endometrium that recreate the tissue's complexity far more faithfully than flat, two-dimensional cell cultures ever could.

The company's platform is built on organoid technology that emerged from Yale School of Medicine's Sozen Lab, where researchers developed techniques to grow 3D structures that mimic the architecture, cell diversity, and hormonal responsiveness of real endometrial tissue. By reproducing the biology of the uterine lining with this level of fidelity, Metri Bio gives pharmaceutical partners a much more predictive testbed for screening drug candidates — reducing reliance on animal models and helping route out ineffective compounds earlier in the development pipeline.

That precision is especially critical for a disease like endometriosis, where treatment options have stagnated for decades. Existing therapies, largely hormonal, come with significant side effects and don't work for every patient. Metri Bio's models allow researchers to study how endometrial tissue behaves and responds to compounds in a system that actually resembles the disease state, opening the door to therapeutics that target the root causes of endometriosis rather than just masking its symptoms.

Metri Bio's $5M pre-seed round was oversubscribed, a signal of strong investor conviction in both the underlying science and the size of the opportunity. With fresh capital in hand, the company is scaling its organoid platform, deepening its pipeline of drug discovery partnerships, and building out the team needed to translate a decade of academic research into real therapeutics for the millions of women living with this disease.

Funding and Backing

The round was led by Pillar VC, with participation from Pace Ventures, Slocum Management, and Navec Investments. The oversubscribed raise reflects growing investor appetite for women's health innovation and for platform technologies that can de-risk drug discovery for historically underfunded conditions like endometriosis.